D J Triggle

发表

Potential folic acid antagonists. I. The antitumor and folic acid reductase inhibitory properties of 6-substituted 2,4-diamino-5-arylazopyrimidines.

J Hampshire, P Hebborn, A M Triggle, 1965, Journal of medicinal chemistry.

Effect of diazoxide on aortic reactivity to calcium in spontaneously hypertensive rats.

D J Triggle, R A Janis, D. Triggle, 1973, Canadian journal of physiology and pharmacology.

Ca2+ channel ligand activities in uterine smooth muscle: influence of hormonal status.

D J Triggle, A L Ruzycky, D J Crankshaw, 1987, Canadian journal of physiology and pharmacology.

Interaction of azimilide with neurohumoral and channel receptors.

D J Triggle, R R Brooks, S F Pong, 2001, Biochemical pharmacology.

Crystal structures and pharmacologic activities of 1,4-dihydropyridine calcium channel antagonists of the isobutyl methyl 2,6-dimethyl-4-(substituted phenyl)-1,4-dihydropyridine-3,5-dicarboxylate (nisoldipine) series.

D J Triggle, R Fossheim, A Joslyn, 1988, Journal of medicinal chemistry.

Sites of action of phencyclidine. I. Effects on the electrical excitability and chemosensitive properties of the neuromuscular junction of skeletal muscle.

D J Triggle, M C Tsai, E X Albuquerque, 1980, Molecular pharmacology.

Calcium channel activation in vascular smooth muscle by BAY K 8644.

D J Triggle, C M Su, V C Swamy, 1984, Canadian journal of physiology and pharmacology.

Potential folic acid antagonists. 5. Synthesis and dihydrofolate reductase inhibitory activities of 2-amino-4,6-substituted-5-arylazopyrimidines.

D J Triggle, S S Chatterjee, S Ludwig, 1971, Journal of medicinal chemistry.

Mechanism of action of benzilylcholine mustard at the muscarinic receptor.

D J Triggle, S K Gupta, J F Moran, 1976, Molecular pharmacology.

Division of Medicinal Chemistry--integrins: past, present and future.

D J Triggle, D P Rotella, 2000, IDrugs : the investigational drugs journal.

Potential folic acid antagonists. 3. The antitumor and folate reductase inhibitory properties of some irreversibly acting 6-N-substituted 2,4,6-triamino-5-(4-carbethoxyphenylazo)pyrimidines.

J Hampshire, P Hebborn, A M Triggle, 1968, Journal of medicinal chemistry.

Studies on the cholinergic receptor. IV. The synthesis and muscarinic activity of 3,7-dimethyl-2,4-dioxo-7-azaspiro[3.4]octane methiodide.

D J Triggle, S S Chatterjee, J F Moran, 1969, Journal of medicinal chemistry.

Pharmacological receptors: a century of discovery--and more.

D J Triggle, D. Triggle, 2000, Pharmaceutica acta Helvetiae.

The action of the ionophores, X-537A and A-23187, on smooth muscle.

D J Triggle, V C Swamy, M Ticku, 1975, Canadian journal of physiology and pharmacology.

Calcium utilization in contractions of intestinal smooth muscle of the guinea pig

D J Triggle, R. Ticku, A. M. Triggle, 1975 .

1,4-Benzodioxanes as reversible and irreversible antagonists at adrenergic receptors.

D J Triggle, B P Avner, 1974, Journal of medicinal chemistry.

Synthesis and muscarinic receptor activity of ester derivatives of 2-substituted 2-azabicyclo[2.2.1]heptan-5-ol and -6-ol.

D J Triggle, F I Carroll, P Abraham, 1992, Journal of medicinal chemistry.

Chemical and pharmacological approaches to the definition and quantitation of calcium channels.

A M Triggle, D J Triggle, R A Janis, 1983, Cold Spring Harbor symposia on quantitative biology.

Calcium channels in smooth muscle. Properties and regulation.

A M Triggle, D J Triggle, A Joslyn, 1989, Annals of the New York Academy of Sciences.

Synthetic Organic Ligands active at Voltage‐Gated Calcium Channels a

D J Triggle, A Rutledge, W Zheng, 1991, Annals of the New York Academy of Sciences.

New developments in Ca2+ channel antagonists.

D J Triggle, R A Janis, D. Triggle, 1984, Journal of medicinal chemistry.

Pharmacologic and radioligand binding analysis of the actions of 1,4-dihydropyridine activator-antagonist pairs in smooth muscle.

D J Triggle, A Rutledge, C M Su, 1986, The Journal of pharmacology and experimental therapeutics.

Crystal structures of calcium channel antagonists: 2,6-dimethyl-3,5-dicarbomethoxy-4-[2-nitro-, 3-cyano-, 4-(dimethylamino)-, and 2,3,4,5,6-pentafluorophenyl]-1,4-dihydropyridine.

A M Triggle, D J Triggle, A. M. Triggle, 1980, Journal of medicinal chemistry.

6-substituted 2,4-diamino-5-(4-carbethoxyphenylazo)pyrimidines as potential precursors of tetrahydropteridine antimetabolites.

J Hampshire, P Hebborn, A M Triggle, 1966, Journal of medicinal chemistry.

Tricarbonylchromium complexes of Hantzsch esters possess robust calcium antagonist activity.

D J Triggle, Y W Kwon, T L Hubler, 1992, Journal of medicinal chemistry.

The action of lanthanum and the lanthanides on contraction in the intestinal smooth muscle of the guinea pig

D J Triggle, Chris R. Triggle, 1973 .

Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.

D J Triggle, D. Triggle, Jiesheng Kang, 2001, Molecular pharmacology.

1,4-Dihydropyridine antagonist activities at the calcium channel: a quantitative structure-activity relationship approach.

A M Triggle, D J Triggle, A J Solo, 1988, Journal of medicinal chemistry.